United States Patent 8,283,362: Indacaterol-Tiotropium Inhalation Combination Patent Analysis

U.S. Patent No. 8,283,362 covers inhalable pharmaceutical compositions combining the long-acting beta-2 agonist indacaterol, including indacaterol maleate, with an anticholinergic or antimuscarinic agent. The strongest commercial embodiment is an inhaled dry-powder combination of indacaterol maleate and tiotropium bromide for chronic obstructive pulmonary disease.

The patent does not claim indacaterol alone, tiotropium alone, a specific inhaler device, or a manufacturing process. Its central requirement is the presence of both active agents in an inhalable composition. The patent’s 20-year term appears to have ended in February 2024, subject to the official USPTO term calculation and any recorded adjustment.

What drug and combination does U.S. Patent 8,283,362 protect?

The compound identified in the claims is indacaterol, specifically the R-enantiomer:

(R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one

The patent protects that compound in free, salt, or solvate form when combined with an inhalable anticholinergic or antimuscarinic agent. The claims expressly identify:

Ipratropium bromide
Oxitropium bromide
Tiotropium bromide

The most specific claimed combination is indacaterol maleate plus tiotropium bromide in a dry-powder inhalation formulation.

Patent element	Scope under the claims
Beta-2 agonist	Indacaterol in free, salt, or solvate form
Preferred salt	Indacaterol maleate
Second active ingredient	Anticholinergic or antimuscarinic agent
Named second agents	Ipratropium bromide, oxitropium bromide, tiotropium bromide
Preferred second agent	Tiotropium bromide
Administration route	Inhalable
Formulation	Any inhalable carrier under claim 1; dry powder under dependent claims
Dose	1 microgram to 5,000 micrograms daily for indacaterol in claims 3 and 7
Therapeutic use	Obstructive or inflammatory airways disease
Express disease limitation	Chronic obstructive pulmonary disease or chronic obstructive airways disease

The use of “comprising” makes the composition claims open-ended. A product containing the claimed combination and additional active or inactive ingredients could still fall within the literal scope if all required elements are present.

How are the 20 claims structured?

Claims 1 through 14 are composition claims. Claims 15 through 20 are method-of-treatment claims.

Composition claims

Claim 1 is the principal composition claim. It requires:

Indacaterol in free, salt, or solvate form;
An anticholinergic or antimuscarinic agent; and
A pharmaceutically acceptable carrier in inhalable form.

Claims 2 through 4 narrow claim 1 by adding a daily dose, a dose range, and a dry-powder formulation.

Claims 5 through 8 narrow the indacaterol component to indacaterol maleate and then add the same dose and dry-powder limitations.

Claims 9 through 10 narrow the second active ingredient to named anticholinergic agents and then specifically to tiotropium bromide.

Claims 11 through 13 define the principal commercial combination:

Indacaterol plus tiotropium bromide;
Indacaterol maleate plus tiotropium bromide;
The same combination in dry-powder form.

Claims 14 adds a dry-powder limitation to claim 1 without requiring a particular anticholinergic.

Method claims

Claims 15 through 20 cover treatment of obstructive or inflammatory airways disease by administering a composition within the scope of claim 1, claim 5, or claim 9.

The method claims are narrower in practical enforcement than a broad product claim because infringement requires evidence that the composition was administered for the claimed therapeutic purpose. Claims 16, 18, and 20 expressly identify chronic obstructive pulmonary disease or chronic obstructive airways disease.

What are the key claim limitations?

The patent’s enforceable scope depends on several cumulative limitations.

Both active ingredients are required

A formulation containing indacaterol alone does not meet claim 1. A formulation containing tiotropium alone does not meet claim 1. The composition must contain indacaterol and an anticholinergic or antimuscarinic agent.

This distinction separates the patent from patents covering Arcapta Neohaler, indacaterol monotherapy, Spiriva, tiotropium monotherapy, or other long-acting bronchodilator products.

The composition must be inhalable

The claims do not cover an oral tablet, injectable formulation, transdermal product, or other non-inhaled dosage form. The carrier must be in inhalable form.

A dry-powder product is expressly covered by claims 4, 8, 13, and 14. Metered-dose and nebulized products may fall within claim 1 if they otherwise meet the inhalable-carrier requirement, even though the dependent claims emphasize dry powder.

Claim 1 is broader than the tiotropium claims

Claim 1 covers any qualifying anticholinergic or antimuscarinic agent. Claim 9 limits the second ingredient to ipratropium bromide, oxitropium bromide, or tiotropium bromide. Claim 10 then narrows the claim to tiotropium bromide.

A design-around using a different antimuscarinic would need to address the potentially broad language of claim 1, not only claims 9 and 10.

Dose limitations apply only to selected dependent claims

The 1-to-5,000-microgram daily-dose range appears in claims 3 and 7. Claim 1 does not contain that numerical range. A product outside the range could avoid claims 3 and 7 while potentially remaining within claim 1 or another independent claim.

The salt limitation matters

Indacaterol maleate is required by claims 5 through 8 and claim 12. A different indacaterol salt, free-base indacaterol, or another solvate may avoid those narrower claims but could remain within claim 1 or claim 11, depending on the formulation and claim construction.

What patent covers the indacaterol active ingredient itself?

U.S. Patent 8,283,362 is not the principal composition-of-matter patent for indacaterol. It covers the combination of indacaterol with an anticholinergic or antimuscarinic agent.

Separate indacaterol patent families cover the molecule, its salts, pharmaceutical formulations, and inhaled use. Those families are more relevant to products containing indacaterol without tiotropium or another antimuscarinic.

Patent category	Relevance to indacaterol products
Composition-of-matter patents	Protect indacaterol and related chemical structures
Salt and crystal-form patents	Protect indacaterol maleate or particular solid forms
Formulation patents	Protect inhalable powders, excipient systems, particle properties, or dose delivery
Combination patents	Protect indacaterol with tiotropium or another anticholinergic
Method-of-use patents	Protect treatment of COPD, asthma, or other airway conditions
Device patents	Protect inhalers, capsules, metering systems, or dose-counter mechanisms

A generic indacaterol product could face the composition-of-matter and formulation estates even if it does not practice the claims of U.S. Patent 8,283,362.

When did U.S. Patent 8,283,362 expire?

The patent’s ordinary 20-year term appears to have ended in February 2024, based on the earliest priority and international filing information associated with the patent family. No patent-term extension for the combination claim is apparent from the patent’s role in the FDA-approved product landscape.

Milestone	Approximate timing
Earliest family priority	February 2003
U.S. patent grant	September 2012
Base statutory expiration	February 2024
Current status for ordinary infringement analysis	Expired after the base term, subject to official USPTO term records

Patent-term adjustment can alter the calculated expiration date. Patent-term extension under 35 U.S.C. § 156 is generally tied to regulatory review of an approved product and does not automatically attach to a combination patent that was not used to support an approved combination product.

Because U.S. Patent 8,283,362 appears to have expired, it should not presently block a new U.S. product solely on the basis of this patent. Earlier infringement, damages, and litigation analyses remain separate questions.

What is the Orange Book status of U.S. Patent 8,283,362?

The patent is not the principal Orange Book patent for Arcapta Neohaler, whose active ingredient is indacaterol. Arcapta contains indacaterol without tiotropium or another anticholinergic agent. A generic indacaterol product therefore would not inherently practice the central combination limitation of U.S. Patent 8,283,362.

The patent also is not expected to function as an Orange Book barrier for Spiriva, because Spiriva contains tiotropium and does not contain indacaterol.

Product	Active ingredient	Relationship to U.S. 8,283,362
Arcapta Neohaler	Indacaterol	Does not contain the required anticholinergic component
Spiriva HandiHaler or Respimat	Tiotropium	Does not contain the required indacaterol component
Ultibro Breezhaler, outside the U.S.	Indacaterol plus glycopyrronium	Potentially relevant to broad combination concepts, but not the named tiotropium embodiment
Anoro Ellipta	Vilanterol plus umeclidinium	Different beta-2 agonist and antimuscarinic pair
Stiolto Respimat	Olodaterol plus tiotropium	Contains tiotropium but not indacaterol

The FDA Orange Book lists patents submitted by NDA holders for approved products. A patent directed to a combination that was never approved as the subject of the relevant NDA may not appear as a blocking patent against a monotherapy product.

What Paragraph IV challenges are relevant?

A Paragraph IV certification is directed to patents listed for an FDA-approved drug product. The commercial relevance of a Paragraph IV challenge to U.S. Patent 8,283,362 depends on the existence of an approved reference product whose listing includes this patent.

For an indacaterol-only ANDA:

The ANDA applicant would generally address patents listed for the indacaterol reference product.
U.S. Patent 8,283,362 would not ordinarily be implicated because the ANDA product would not contain the required anticholinergic agent.
A Paragraph IV certification against the combination patent would not by itself establish infringement of the patent’s claims.

For a future indacaterol-antimuscarinic combination:

There is no conventional U.S. ANDA pathway unless an approved reference listed drug exists for the same combination.
The sponsor may need an NDA, a 505(b)(2) application, or another regulatory pathway depending on the product and reference products.
Patent disputes would likely focus on separate active-ingredient, formulation, device, and use patents in addition to U.S. Patent 8,283,362.

What formulation and device barriers remain after expiration?

Expiration of the combination patent does not eliminate other intellectual-property barriers.

Formulation patents

A later patent may claim:

Carrier particle size;
Lactose or other excipient systems;
Engineered powder morphology;
Particle coating;
Dose uniformity;
Moisture control;
Aerosol performance;
Co-formulated active particles;
Separate reservoirs for incompatible actives.

A product can avoid U.S. Patent 8,283,362 yet infringe a later formulation patent.

Inhaler patents

The patent claims do not require a particular inhaler. A competing product could use a capsule-based dry-powder inhaler, a blister-strip device, a reservoir inhaler, a metered-dose inhaler, or a nebulizer. Separate patents may cover the selected device and dose-delivery mechanism.

Manufacturing and solid-state barriers

Indacaterol maleate manufacturing may involve separate protection for:

Chemical intermediates;
Enantiomer resolution;
Salt formation;
Crystalline polymorphs;
Particle engineering;
Micronization;
Blend uniformity;
Low-dose content uniformity.

Those rights can create development and freedom-to-operate risks even after the combination patent expires.

How strong is the patent estate for an indacaterol-tiotropium product?

The patent is technically strong against the exact combination described in claims 11 through 13, particularly a dry-powder product containing indacaterol maleate and tiotropium bromide. Its practical commercial strength is lower because:

The patent appears expired.
No major U.S. approved product is identified as depending on the claimed combination.
Indacaterol monotherapy and tiotropium monotherapy do not meet the central combination limitation.
Later formulation, device, and active-ingredient patents may control market entry independently.
The claims do not cover a specific inhaler or manufacturing process.

Risk category	Assessment
Exact indacaterol maleate-tiotr opium dry powder	Historically high claim overlap; current risk reduced by expiration
Indacaterol monotherapy	Outside the core combination claims
Tiotropium monotherapy	Outside the core combination claims
Indacaterol plus glycopyrronium	Potential issue under broad claim 1, subject to claim construction and product details
Indacaterol plus a different antimuscarinic	Potential issue under claim 1
Non-inhaled combination	Outside the express inhalable-composition claims
Device-only design	Generally outside the claims unless the composition limitations are met

Which companies are relevant to the competitive landscape?

Novartis is the principal company associated with indacaterol development and the patent family. Boehringer Ingelheim is the major commercial participant associated with tiotropium. Other long-acting bronchodilator competitors include AstraZeneca, GlaxoSmithKline, and firms marketing generic inhaled products.

The relevant competitive products use different active-ingredient pairs:

Product or product family	Company association	Combination
Arcapta Neohaler	Novartis	Indacaterol
Spiriva	Boehringer Ingelheim	Tiotropium
Ultibro Breezhaler	Novartis	Indacaterol plus glycopyrronium
Anoro Ellipta	GlaxoSmithKline	Vilanterol plus umeclidinium
Stiolto Respimat	Boehringer Ingelheim and Eli Lilly	Olodaterol plus tiotropium
Bevespi Aerosphere	AstraZeneca	Formoterol plus glycopyrrolate

The most direct technical comparison is between indacaterol-glycopyrronium and the claimed indacaterol-tiotropium combination. Glycopyrronium is not one of the three anticholinergics expressly named in claim 9, but claim 1 is broader and may reach an inhalable indacaterol combination with another antimuscarinic depending on construction.

What licensing and settlement issues are identifiable?

U.S. Patent 8,283,362 is associated with the Novartis indacaterol patent portfolio. The patent itself does not establish a license, co-development agreement, or settlement agreement.

No licensing arrangement should be inferred merely from:

Commercial distribution of indacaterol products;
Use of a third-party inhaler;
A separate patent assigned to a device manufacturer;
Marketing rights in a particular country;
A regulatory submission by another company.

Any commercial diligence should distinguish patent ownership, product commercialization rights, inhaler technology licenses, and regional distribution agreements.

What is the geographic coverage?

U.S. Patent 8,283,362 provides rights only in the United States. The underlying PCT and national patent family may include corresponding patents in Europe, Canada, Japan, Australia, and other jurisdictions, but each jurisdiction has separate claims, term calculations, prosecution histories, and validity outcomes.

A U.S. expiration does not establish expiration elsewhere. Foreign family members can differ in:

Granted claim scope;
Patent-term adjustment;
Supplementary protection certificate status;
Opposition outcomes;
National-phase maintenance;
Regulatory exclusivity;
Combination-product approval status.

Key Takeaways

U.S. Patent 8,283,362 covers inhalable combinations of indacaterol with an anticholinergic or antimuscarinic agent.
The most specific claims cover indacaterol maleate plus tiotropium bromide in a dry-powder formulation.
The patent does not cover indacaterol alone, tiotropium alone, a specific inhaler device, or manufacturing methods.
Claims 1 and 15 are the principal broad composition and treatment claims.
Claims 9 through 13 provide the strongest protection for tiotropium and dry-powder embodiments.
The claimed daily-dose range is 1 to 5,000 micrograms, but only selected dependent claims include that limitation.
The patent’s ordinary U.S. term appears to have ended in February 2024.
The patent is not the principal Orange Book barrier for Arcapta Neohaler or Spiriva.
Biosimilar analysis is not applicable because indacaterol and tiotropium are small-molecule drugs, not biologics.
Remaining freedom-to-operate risks are more likely to arise from separate active-ingredient, formulation, solid-state, device, and manufacturing patents.

Frequently Asked Questions

Does U.S. Patent 8,283,362 cover Arcapta Neohaler?

No. Arcapta Neohaler contains indacaterol but not an anticholinergic or antimuscarinic agent. The combination requirement is central to the patent.

Does the patent cover Spiriva?

No. Spiriva contains tiotropium but not indacaterol. The patent requires both active-ingredient categories in an inhalable composition.

Could a product containing indacaterol and glycopyrronium infringe?

Potentially. Claim 1 broadly covers an anticholinergic or antimuscarinic agent, while claim 9 specifically lists other agents. Infringement would depend on claim construction, formulation facts, and patent term.

Is a biosimilar filing required to challenge this patent?

No. Indacaterol and tiotropium are small-molecule drugs. The relevant regulatory pathways are generally ANDA, 505(b)(2), or NDA pathways, not biosimilar approval under the Public Health Service Act.

Does patent expiration eliminate all launch risk for an indacaterol-tiotropium inhaler?

No. Later patents may cover indacaterol salts, polymorphs, powder formulations, excipients, inhaler devices, manufacturing processes, or approved methods of use.

References

U.S. Patent No. 8,283,362. (2012). Pharmaceutical compositions comprising a beta-2 adrenergic receptor agonist and an anticholinergic agent. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (2011). Arcapta Neohaler (indacaterol maleate) prescribing information. FDA.
U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. FDA.
U.S. Food and Drug Administration. (2023). Spiriva HandiHaler and Spiriva Respimat prescribing information. FDA.
United States Code, 35 U.S.C. §§ 154, 156, and 271.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	9913083.3	Jun 4, 1999

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1183240	⤷ Start Trial	C300437	Netherlands	⤷ Start Trial
European Patent Office	1183240	⤷ Start Trial	CA 2010 00006	Denmark	⤷ Start Trial
European Patent Office	1183240	⤷ Start Trial	91651	Luxembourg	⤷ Start Trial
European Patent Office	1183240	⤷ Start Trial	SPC009/2010	Ireland	⤷ Start Trial
European Patent Office	1183240	⤷ Start Trial	10C0006	France	⤷ Start Trial
European Patent Office	1183240	⤷ Start Trial	SPC/GB10/009	United Kingdom	⤷ Start Trial
European Patent Office	1183240	⤷ Start Trial	C01183240/01	Switzerland	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,283,362

Summary for Patent: 8,283,362